Patients with multiple myeloma were randomly assigned at a one-to-one ratio to receive either aprepitant ( 125 mg orally on day 1 and 80 mg orally on days 2 to 4 ) , granisetron ( 2 mg orally on days 1 to 4 ) , and dexamethasone ( 4 mg orally on day 1 and 2 mg orally on days 2 to 3 ) or matching placebo , granisetron ( 2 mg orally on days 1 to 4 ) , and dexamethasone ( 8 mg orally on day 1 and 4 mg orally on days 2 to 3 ) .